• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

利用外周血细胞计数改善国际预后指数评分:一项涉及 520 例弥漫性大 B 细胞淋巴瘤患者的大型多中心研究结果。

Improving the international prognostic index score using peripheral blood counts: Results of a large multicenter study involving 520 patients with diffuse large B cell lymphoma.

机构信息

Fondazione Italiana Linfomi, Onlus, Modena, Italy.

Dipartimento di Scienze Mediche e Chirurgiche Materno-Infantili e dell'Adulto, Università di Modena e Reggio Emilia, Modena, Italy.

出版信息

Hematol Oncol. 2020 Oct;38(4):439-445. doi: 10.1002/hon.2757. Epub 2020 Jun 17.

DOI:10.1002/hon.2757
PMID:32495944
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7687198/
Abstract

The main purpose of this study was to assess whether it is possible to improve the prognostic impact of international prognostic index (IPI) score by combining it with peripheral blood counts. Thus, we evaluated the prognostic power of lymphocyte, neutrophil, and monocyte counts in 520 patients with diffuse large B cell lymphoma treated with R-CHOP, confirming that these parameters have a strong impact on overall survival (OS). Using revised IPI (R-IPI), 44% of patients were categorized as poor-risk and showed an OS at 5 years of 46%. As OS at 5 years of the 520 patients is 67%, it is clearly evident that R-IPI tends to overestimate the proportion of patients with poor prognosis. Accordingly, in an attempt to improve the discriminating power of R-IPI, we evaluated and compared three different scores by combining the neutrophil lymphocyte ratio (NLR) and absolute monocyte count (AMC) with the following values: (a) IPI score 3-5, (b) age > 60 years and performance status, (c) age  ≥ 65 years and LDH > ULN. The three indexes studied, had a similar 5 years OS for the high-risk group (46%-52%), but the proportion of patients classified as poor-risk were 37%, 20%, and 32%, respectively, which are lower than 44% identified with R-IPI. Thus, while R-IPI overestimates the number of high-risk patients, after applying our models, it is possible to recognize patients who are truly at high-risk. Of the three scores, the most accurate appears to be that based on NLR, AMC, LDH > ULN and age ≥ 65 years, which identifies 32% of high-risk patients, correlating well with what is seen in clinical practice.

摘要

本研究的主要目的是评估是否可以通过结合外周血计数来改善国际预后指数(IPI)评分的预后影响。因此,我们评估了淋巴细胞、中性粒细胞和单核细胞计数在 520 例接受 R-CHOP 治疗的弥漫性大 B 细胞淋巴瘤患者中的预后能力,证实这些参数对总生存(OS)有很强的影响。使用修订的 IPI(R-IPI),44%的患者被归类为不良风险,5 年 OS 为 46%。由于 520 例患者的 5 年 OS 为 67%,显然 R-IPI 倾向于高估预后不良患者的比例。因此,为了提高 R-IPI 的判别能力,我们评估并比较了三种不同的评分,方法是将中性粒细胞与淋巴细胞比值(NLR)和绝对单核细胞计数(AMC)与以下值相结合:(a)IPI 评分 3-5,(b)年龄>60 岁和表现状态,(c)年龄≥65 岁和乳酸脱氢酶(LDH)>正常值上限(ULN)。研究的三个指标对高危组的 5 年 OS 相似(46%-52%),但分类为不良风险的患者比例分别为 37%、20%和 32%,低于 R-IPI 确定的 44%。因此,虽然 R-IPI 高估了高危患者的数量,但在应用我们的模型后,可以识别出真正处于高危状态的患者。在这三个评分中,似乎最准确的是基于 NLR、AMC、LDH>ULN 和年龄≥65 岁的评分,该评分识别出 32%的高危患者,与临床实践中的情况相符。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8d21/7687198/8f6dce52049a/HON-38-439-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8d21/7687198/8f6dce52049a/HON-38-439-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8d21/7687198/8f6dce52049a/HON-38-439-g001.jpg

相似文献

1
Improving the international prognostic index score using peripheral blood counts: Results of a large multicenter study involving 520 patients with diffuse large B cell lymphoma.利用外周血细胞计数改善国际预后指数评分:一项涉及 520 例弥漫性大 B 细胞淋巴瘤患者的大型多中心研究结果。
Hematol Oncol. 2020 Oct;38(4):439-445. doi: 10.1002/hon.2757. Epub 2020 Jun 17.
2
An inflammation-based cumulative prognostic score system in patients with diffuse large B cell lymphoma in rituximab era.利妥昔单抗时代弥漫性大 B 细胞淋巴瘤患者基于炎症的累积预后评分系统。
BMC Cancer. 2018 Jan 2;18(1):5. doi: 10.1186/s12885-017-3931-z.
3
A new prognostic model using the NCCN-IPI and neutrophil-to-lymphocyte ratio in diffuse large B-cell lymphoma.一种使用NCCN-IPI和中性粒细胞与淋巴细胞比值的弥漫性大B细胞淋巴瘤新预后模型。
Tumori. 2018 Aug;104(4):292-299. doi: 10.5301/tj.5000694. Epub 2018 May 8.
4
Neutrophil to lymphocyte ratio improves prognostic prediction of International Prognostic Index for patients with diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone.中性粒细胞与淋巴细胞比值改善了接受利妥昔单抗、环磷酰胺、阿霉素、长春新碱和泼尼松治疗的弥漫性大B细胞淋巴瘤患者国际预后指数的预后预测。
Leuk Lymphoma. 2015 Jul;56(7):2032-8. doi: 10.3109/10428194.2014.982642. Epub 2015 Jan 21.
5
A new prognostic score for elderly patients with diffuse large B-cell lymphoma treated with R-CHOP: the prognostic role of blood monocyte and lymphocyte counts is absent.一种用于接受R-CHOP治疗的老年弥漫性大B细胞淋巴瘤患者的新预后评分:血液单核细胞和淋巴细胞计数无预后作用。
PLoS One. 2014 Jul 24;9(7):e102594. doi: 10.1371/journal.pone.0102594. eCollection 2014.
6
The absolute monocyte and lymphocyte prognostic index for patients with diffuse large B-cell lymphoma who receive R-CHOP.R-CHOP 治疗弥漫性大 B 细胞淋巴瘤患者的绝对单核细胞和淋巴细胞预后指数。
Clin Lymphoma Myeloma Leuk. 2013 Feb;13(1):15-8. doi: 10.1016/j.clml.2012.09.009. Epub 2012 Nov 6.
7
International prognostic indices in diffuse large B-cell lymphoma: a comparison of IPI, R-IPI, and NCCN-IPI.弥漫性大 B 细胞淋巴瘤的国际预后指数:IPI、R-IPI 和 NCCN-IPI 的比较。
Blood. 2020 Jun 4;135(23):2041-2048. doi: 10.1182/blood.2019002729.
8
New prognosis score including absolute lymphocyte/monocyte ratio, red blood cell distribution width and beta-2 microglobulin in patients with diffuse large B-cell lymphoma treated with R-CHOP: Spanish Lymphoma Group Experience (GELTAMO).包含绝对淋巴细胞/单核细胞比值、红细胞分布宽度和β-2 微球蛋白的新预后评分在接受 R-CHOP 治疗的弥漫性大 B 细胞淋巴瘤患者中的应用:西班牙淋巴瘤组经验(GELTAMO)。
Br J Haematol. 2020 Mar;188(6):888-897. doi: 10.1111/bjh.16263. Epub 2019 Nov 28.
9
Peripheral blood lymphocyte/monocyte ratio predicts outcome for patients with diffuse large B cell lymphoma after standard first-line regimens.外周血淋巴细胞/单核细胞比值可预测接受标准一线方案治疗后的弥漫性大 B 细胞淋巴瘤患者的预后。
Ann Hematol. 2014 Apr;93(4):617-26. doi: 10.1007/s00277-013-1916-9. Epub 2013 Oct 19.
10
Neutrophil/Lymphocyte Ratio, Lymphocyte/Monocyte Ratio, and Absolute Lymphocyte Count/Absolute Monocyte Count Prognostic Score in Diffuse Large B-Cell Lymphoma: Useful Prognostic Tools in the Rituximab Era.弥漫性大B细胞淋巴瘤中的中性粒细胞/淋巴细胞比值、淋巴细胞/单核细胞比值及绝对淋巴细胞计数/绝对单核细胞计数预后评分:利妥昔单抗时代的有用预后工具
Medicine (Baltimore). 2015 Jun;94(24):e993. doi: 10.1097/MD.0000000000000993.

引用本文的文献

1
MicroRNAs implicated in canine diffuse large B-cell lymphoma prognosis.与犬弥漫性大 B 细胞淋巴瘤预后相关的 microRNAs。
FEBS Open Bio. 2024 Nov;14(11):1899-1913. doi: 10.1002/2211-5463.13887. Epub 2024 Sep 1.
2
Biological signatures of the International Prognostic Index in diffuse large B-cell lymphoma.弥漫性大 B 细胞淋巴瘤中国际预后指数的生物学特征。
Blood Adv. 2024 Apr 9;8(7):1587-1599. doi: 10.1182/bloodadvances.2023011425.

本文引用的文献

1
Beware of the neutrophil/lymphocyte ratio in diffuse large B-cell lymphoma.谨防弥漫性大B细胞淋巴瘤中的中性粒细胞/淋巴细胞比值。
Leuk Lymphoma. 2019 Dec;60(14):3345-3346. doi: 10.1080/10428194.2019.1668940. Epub 2019 Sep 26.
2
Progression-free survival at 24 months (PFS24) and subsequent outcome for patients with diffuse large B-cell lymphoma (DLBCL) in the real-world setting.真实世界中弥漫性大B细胞淋巴瘤(DLBCL)患者的24个月无进展生存期(PFS24)及后续转归。
Ann Oncol. 2019 Jan 1;30(1):151-152. doi: 10.1093/annonc/mdy482.
3
Diffuse large B-cell lymphoma: 10 years' real-world clinical experience with rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisolone.
弥漫性大B细胞淋巴瘤:利妥昔单抗联合环磷酰胺、多柔比星、长春新碱和泼尼松龙的10年真实世界临床经验
Oncol Lett. 2018 Mar;15(3):3602-3609. doi: 10.3892/ol.2018.7774. Epub 2018 Jan 11.
4
Clinical Impact of the Cell-of-Origin Classification and the MYC/ BCL2 Dual Expresser Status in Diffuse Large B-Cell Lymphoma Treated Within Prospective Clinical Trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group.在德国高级非霍奇金淋巴瘤研究组的前瞻性临床试验中,针对弥漫性大 B 细胞淋巴瘤进行治疗,探讨了细胞起源分类和 MYC/BCL2 双表达状态的临床影响。
J Clin Oncol. 2017 Aug 1;35(22):2515-2526. doi: 10.1200/JCO.2016.70.3660. Epub 2017 May 19.
5
Validation of the NCCN-IPI for diffuse large B-cell lymphoma (DLBCL): the addition of β -microglobulin yields a more accurate GELTAMO-IPI.NCCN国际预后指数(NCCN-IPI)在弥漫性大B细胞淋巴瘤(DLBCL)中的验证:添加β-微球蛋白可产生更准确的GELTAMO国际预后指数(GELTAMO-IPI)。
Br J Haematol. 2017 Mar;176(6):918-928. doi: 10.1111/bjh.14489. Epub 2017 Jan 20.
6
NCCN-IPI score-independent prognostic potential of pretreatment uric acid levels for clinical outcome of diffuse large B-cell lymphoma patients.NCCN-IPI评分独立的预处理尿酸水平对弥漫性大B细胞淋巴瘤患者临床结局的预后潜力。
Br J Cancer. 2016 Nov 8;115(10):1264-1272. doi: 10.1038/bjc.2016.325. Epub 2016 Oct 20.
7
Diffuse Large B-Cell Lymphoma in the Elderly: Real World Outcomes of Immunochemotherapy in Asian Population.老年弥漫性大B细胞淋巴瘤:亚洲人群免疫化疗的真实世界结果
Clin Lymphoma Myeloma Leuk. 2016 Sep;16(9):503-510.e3. doi: 10.1016/j.clml.2016.06.003. Epub 2016 Jun 8.
8
Absolute Monocyte Count and Lymphocyte-Monocyte Ratio Predict Outcome in Nodular Sclerosis Hodgkin Lymphoma: Evaluation Based on Data From 1450 Patients.绝对单核细胞计数和淋巴细胞-单核细胞比值可预测结节性硬化型霍奇金淋巴瘤的预后:基于 1450 例患者数据的评估。
Mayo Clin Proc. 2015 Jun;90(6):756-64. doi: 10.1016/j.mayocp.2015.03.025.
9
Defining the best cut-off value for lymphopenia in diffuse large B cell lymphoma treated with immuno-chemotherapy.确定接受免疫化疗的弥漫性大B细胞淋巴瘤中淋巴细胞减少的最佳临界值。
Br J Haematol. 2014 Oct;167(1):133-6. doi: 10.1111/bjh.12930. Epub 2014 May 3.
10
The derived neutrophil to lymphocyte ratio is an independent prognostic factor in patients with diffuse large B-cell lymphoma.中性粒细胞与淋巴细胞比值可作为弥漫性大 B 细胞淋巴瘤患者独立的预后因素。
Br J Cancer. 2014 Jan 21;110(2):369-74. doi: 10.1038/bjc.2013.763. Epub 2013 Dec 19.